Showing 271-280 of 354 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| A multiorgan autoimmune T-cell killing in-vitro platform to improve T1D drug screening | Indiana Biosciences Research Institute | Roberto Mallone | Cures | 01-June-2026 to 31-May-2027 | $196,040.47 |
| Bringing Beta Cell Regenerative Therapy to the Clinic | Icahn School of Medicine at Mount Sinai | Andrew Stewart | Cures | 01-January-2024 to 31-December-2026 | $1,000,000.00 |
| Exploring the Effects of Beta Cell Regenerative Drugs on Cell Fate Decisions in Human Pancreatic Islets | Icahn School of Medicine at Mount Sinai | Esra Karakose | Cures | 01-March-2025 to 28-February-2030 | $999,999.00 |
| Targeting pathogenic Th17 cells as shared mechanisms in MS, SLE and T1D | Icahn School of Medicine at Mount Sinai | Ka Lung Cheung | Cures | 01-September-2026 to 31-August-2027 | $149,950.03 |
| Enhancing Functional Maturation of Stem Cell-Derived Beta Cells Using Harmine for Improved Diabetes Therapy | Icahn School of Medicine at Mount Sinai | Peng Wang | Cures | 01-July-2025 to 31-December-2026 | $305,000.00 |
| Protective Genetic and Pharmacological Interventions to Prevent Cytokine and Autoimmune-based Destruction of β cells. | Icahn School of Medicine at Mount Sinai | Romina Bevacqua | Cures | 01-April-2025 to 31-March-2027 | $559,996.54 |
| Protective Interventions against Loss of Function and Destruction of β cells in Type 1 Diabetes. | Icahn School of Medicine at Mount Sinai | Romina Bevacqua | Cures | 01-March-2026 to 28-February-2031 | $999,999.00 |
| Cardiotoxic Circulating Extracellular Vesicles: New Drivers of Type 1 Diabetes-induced Cardiomyopathy | Icahn School of Medicine at Mount Sinai | Susmita Sahoo | Improving Lives | 01-April-2025 to 30-September-2026 | $199,998.24 |
| Defining antigen-presenting cell – CD8 T cell crosstalk in type 1 diabetes using uLIPSTIC | Icahn School of Medicine at Mount Sinai | Verena van der Heide | Cures | 01-May-2026 to 30-April-2029 | $600,000.00 |
| Development and Preclinical Assessment of a Biovascular Pancreas | Humacyte | Kaleb Naegeli | Cures | 01-April-2023 to 28-February-2027 | $863,333.00 |